Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma

Anti-Cancer Drugs

Volumn 14, Issue 10, 2003, Pages 779-784

  Wenzel, Catharina ^a   Locker, Gottfried J ^a   Bartsch, Rupert ^a   Pluschnig, Ursula ^a   Mader, Robert ^a   Hussian, Dagmar ^a   Kramer, Gero ^a   Marberger, Michael ^a   Lintner, Christian ^b   Rauchenwald, Michael ^b   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b St Poelten Hospital   (Austria)

Author keywords

Capecitabine; Combination therapy; Metastatic renal cell carcinoma; Monotherapy; Second and third line treatment

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; GAMMA INTERFERON; GAMMA1B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NAVELBINE; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METASTASIS; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 12144289948     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200311000-00002     Document Type: Article

References (27)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999; 49:8-31.
2. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22:42-60.
3. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors. Cancer 2001; 15:1569-1576.
4. Negrier S, Escudier B, Lasset C, Douiilard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. Group Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-1278.
5. Schmidinger M, Steger GG, Wenzel C, Locker GJ, Brodowicz T, Budinsky A, et al. Sequential administration of interferon-gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Cancer Immunol Immun 2000; 49:395-400.
6. Jaremtchuk AV, Aman EF, Ponce W, Zarba JJ, Ferro AM, Alvarez R, et al. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma. Am J Clin Oncol 2002; 25:123-125.
7. Schmidinger M, Steger GG, Budinsky AC, Wenzel C, Brodowicz T, Locker GJ, et al. Vinorelbine and interferon-α2c as second-line therapy in metastatic renal cell carcinoma. Anticancer Drugs 2000; 11:175-179.
8. Tourani JM, Pfister C, Berdah J-F, Benhammouda A, Salze P, Monnier A, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. J Clin Oncol 1998; 16:2505-2513.
9. Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Fraincaise d'Immunotherape. J Clin Oncol 1999; 17:2039-2043.
10. Paolorossi F, Villa S, Barni S, Tancini G, Andres M, Lissoni P. Second-line therapy with IFN-α plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. Tumori 1995; 81:45-47.
11. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
12. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al. Clinicopathologic and prognostic significance of an angiogenetic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88:1110-1117.
13. Wenzel C, Locker GJ, Schmidinger M, Schmidinger M, Mader R, Kramer G, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis 2002; 39:48-54.
14. Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000; 83:583-587.
15. Kaplan EL and Meier P. Non parametric estimation for incomplete observations. J Am Stat Ass 1958; 53:457-481.
16. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukine-2 or high-dose interleukine-2 alone. N Engl J Med 1987; 316:898-905.
17. Tourani JM, Lucas V, Mayeur D, Dufour B, DiPalma M, Boaziz C, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in outpatient treatment with metastatic renal cell carcinoma. Results of a multicenter SCAPP I trial. Ann Oncol 1996; 7:525-528.
18. Atzpodien J, Kirchner H, Lopez Hänninen E, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with IFN-α and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A:S6-S8.
19. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG. Immunotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, IFN-α and 5-fluorouracil. J Urol 1996; 156:18-21.
20. Lissoni P, Scardino E, Favini P, Barni S, Tancini G, Baccalin A, et al. Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases. Arch Ital Urol Androl 1995; 67:149-153.
21. Lopez Hanninen E, Poliwoda H, Atzpodien J. Interferon-alpha/5- fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma. Cancer Biother 1995; 10:21-24.
22. Merimsky O, Chaitchik S. Our experience with interferon alpha: renal cell carcinoma. Mol Biother 1992; 4:130-134.
23. Rini BI, Vogelzang NJ, Dumas MC, Wade III JL, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18:2419-2426.
24. Eisen T, Boshoff C, Mak I, Vaughan MM, Johnston SRD, Ahern R, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal, cell ovarian and breast cancer. Br J Cancer 2000; 82:812-817.
25. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002; 20:302-306.
26. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors. Cancer 2001; 15:1567-1576.
27. Frings S. Capecitabine - a novel oral tumor-activated fluoropyrimidine. Onkologie 1998; 21:451-458.